Literature DB >> 19632988

Use of uteroglobin for the engineering of polyvalent, polyspecific fusion proteins.

Elisa Ventura1, Francesca Sassi, Sara Fossati, Arianna Parodi, William Blalock, Enrica Balza, Patrizia Castellani, Laura Borsi, Barbara Carnemolla, Luciano Zardi.   

Abstract

We report a novel strategy to engineer and express stable and soluble human recombinant polyvalent/polyspecific fusion proteins. The procedure is based on the use of a central skeleton of uteroglobin, a small and very soluble covalently linked homodimeric protein that is very resistant to proteolytic enzymes and to pH variations. Using a human recombinant antibody (scFv) specific for the angiogenesis marker domain B of fibronectin, interleukin 2, and an scFv able to neutralize tumor necrosis factor-alpha, we expressed various biologically active uteroglobin fusion proteins. The results demonstrate the possibility to generate monospecific divalent and tetravalent antibodies, immunocytokines, and dual specificity tetravalent antibodies. Furthermore, compared with similar fusion proteins in which uteroglobin was not used, the use of uteroglobin improved properties of solubility and stability. Indeed, in the reported cases it was possible to vacuum dry and reconstitute the proteins without any aggregation or loss in protein and biological activity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19632988      PMCID: PMC2785352          DOI: 10.1074/jbc.M109.025924

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  35 in total

Review 1.  Bispecific and bifunctional single chain recombinant antibodies.

Authors:  J Kriangkum; B Xu; L P Nagata; R E Fulton; M R Suresh
Journal:  Biomol Eng       Date:  2001-09

2.  Differentiation between high- and low-grade astrocytoma using a human recombinant antibody to the extra domain-B of fibronectin.

Authors:  Patrizia Castellani; Laura Borsi; Barbara Carnemolla; Attila Birò; Alessandra Dorcaratto; Giuseppe L Viale; Dario Neri; Luciano Zardi
Journal:  Am J Pathol       Date:  2002-11       Impact factor: 4.307

Review 3.  Rationale for the development of recombinant human CC10 as a therapeutic for inflammatory and fibrotic disease.

Authors:  A L Pilon
Journal:  Ann N Y Acad Sci       Date:  2000       Impact factor: 5.691

4.  Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix.

Authors:  Barbara Carnemolla; Laura Borsi; Enrica Balza; Patrizia Castellani; Raffaella Meazza; Alexander Berndt; Silvano Ferrini; Hartwig Kosmehl; Dario Neri; Luciano Zardi
Journal:  Blood       Date:  2002-03-01       Impact factor: 22.113

5.  Expression of the extra domain B of fibronectin, a marker of angiogenesis, in head and neck tumors.

Authors:  Manfred T Birchler; Dusan Milisavlijevic; Madeleine Pfaltz; Dario Neri; Bernhard Odermatt; Stefan Schmid; Sandro J Stoeckli
Journal:  Laryngoscope       Date:  2003-07       Impact factor: 3.325

6.  Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer.

Authors:  Monica Santimaria; Giovanni Moscatelli; Giuseppe L Viale; Leonardo Giovannoni; Giovanni Neri; Francesca Viti; Alessandra Leprini; Laura Borsi; Patrizia Castellani; Luciano Zardi; Dario Neri; Pietro Riva
Journal:  Clin Cancer Res       Date:  2003-02       Impact factor: 12.531

7.  Selective targeted delivery of TNFalpha to tumor blood vessels.

Authors:  Laura Borsi; Enrica Balza; Barbara Carnemolla; Francesca Sassi; Patrizia Castellani; Alexander Berndt; Hartwig Kosmehl; Attila Biro; Annalisa Siri; Paola Orecchia; Jessica Grassi; Dario Neri; Luciano Zardi
Journal:  Blood       Date:  2003-08-21       Impact factor: 22.113

8.  "Blastokinin": inducer and regulator of blastocyst development in the rabbit uterus.

Authors:  R S Krishnan; J C Daniel
Journal:  Science       Date:  1967-10-27       Impact factor: 47.728

9.  Expression of the oncofetal ED-B-containing fibronectin isoform in hematologic tumors enables ED-B-targeted 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma patients.

Authors:  Stefanie Sauer; Paola A Erba; Mario Petrini; Andreas Menrad; Leonardo Giovannoni; Chiara Grana; Burkhard Hirsch; Luciano Zardi; Giovanni Paganelli; Giuliano Mariani; Dario Neri; Horst Dürkop; Hans D Menssen
Journal:  Blood       Date:  2009-01-08       Impact factor: 22.113

10.  Selective targeting of tumoral vasculature: comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin.

Authors:  Laura Borsi; Enrica Balza; Marco Bestagno; Patrizia Castellani; Barbara Carnemolla; Attila Biro; Alessandra Leprini; Jorge Sepulveda; Oscar Burrone; Dario Neri; Luciano Zardi
Journal:  Int J Cancer       Date:  2002-11-01       Impact factor: 7.396

View more
  3 in total

Review 1.  Antibody vectors for imaging.

Authors:  Tove Olafsen; Anna M Wu
Journal:  Semin Nucl Med       Date:  2010-05       Impact factor: 4.446

2.  Selective targeted delivery of the TNF-alpha receptor p75 and uteroglobin to the vasculature of inflamed tissues: a preliminary report.

Authors:  Elisa Ventura; Enrica Balza; Laura Borsi; Giorgia Tutolo; Barbara Carnemolla; Patrizia Castellani; Luciano Zardi
Journal:  BMC Biotechnol       Date:  2011-11-10       Impact factor: 2.563

3.  Use of the uteroglobin platform for the expression of a bivalent antibody against oncofetal fibronectin in Escherichia coli.

Authors:  Elisa Ventura; Mattia Riondato; Gianmario Sambuceti; Annalisa Salis; Gianluca Damonte; Cinzia Cordazzo; Hüseyin Besir; Vito Pistoia; Luciano Zardi
Journal:  PLoS One       Date:  2013-12-19       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.